Franklin Covey Co.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul S. Walker
- Full Time Employees
- 1,084
- Sector
- Industrials
- Industry
- Consulting Services
- Address
- 2200 West Parkway Boulevard Salt Lake City UT United States of America 84119-2331
- IPO Date
- Jun 3, 1992
- CIK
- 0000886206
- Website
- franklincovey.com
- Similar Companies
- Business
- Franklin Covey Co. Franklin Covey Co. (FC) operates as a global performance improvement company, providing training, consulting, and assessment services focused on leadership development, execution, productivity, sales performance, customer loyalty, individual effectiveness, and educational solutions to organizations and individuals worldwide. The company offers core programs including The 7 Habits of Highly Effective People, Leading at the Speed of Trust, The 4 Disciplines of Execution, and the Leader in Me whole-school transformation model; it delivers these through in-person workshops, live-online training, digital subscriptions, coaching, and customized content via direct offices, international licensees in over 120 countries, and its Education Practice segment serving enterprise, government, and school clients across North America, Europe, Asia-Pacific, Latin America, and the Middle East. Founded in 1983 through the predecessor Franklin Quest and merged with Covey Leadership Center in 1997 to form its current structure, Franklin Covey Co. is headquartered in Salt Lake City, Utah, with approximately 1,100 employees and operations emphasizing behavior change for sustained results. In recent developments, the company reported fiscal 2025 third-quarter revenue of $67.1 million amid macroeconomic challenges, executed a sales transformation in its North America Enterprise division yielding new client growth and 7% higher deferred subscription revenue, and continues expanding multi-year subscription contracts while guiding full-year 2025 revenue at $265-275 million and Adjusted EBITDA at $28-33 million.
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
80% of Individual Contributors Say Their Manager's Approach to AI is Hands-Off, FranklinCovey Research Finds
80% of Individual Contributors Say Their Manager's Approach to AI is Hands-Off, FranklinCovey Research Finds
Diploma H1 Earnings Call Highlights
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
Firm Capital Mortgage Investment Corporation Announces Q1/2026 Results and Declares Monthly Cash Dividends for July, August and September 2026
Franklin Covey Q2 Earnings Call Highlights
Top 2 Industrials Stocks You May Want To Dump In Q2
Franklin Covey Co. (FC) Q2 2026 Earnings Call Transcript
Franklin Covey (FC) Reports Q2 Loss, Tops Revenue Estimates
Franklin Covey Reports Second Quarter Fiscal 2026 Financial Results
FranklinCovey Provides Customized Solutions for Healthcare Organizations to Solve Key Issues: Nurse Retention and Patient Satisfaction
Franklin Covey: What I'm Looking For In Q2 Earnings
Should Value Investors Buy Franklin Covey (FC) Stock?
Franklin Covey (FC) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Wall Street Analysts Believe Franklin Covey (FC) Could Rally 99.09%: Here's is How to Trade
Franklin Covey (FC) Surges 11.5%: Is This an Indication of Further Gains?
Franklin Covey to Report Second Quarter Fiscal 2026 Results
Here's Why Franklin Covey (FC) Is a Great 'Buy the Bottom' Stock Now